Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Chi Sheng Pharma & Biotech Co., Ltd. (4111:TWSE), powered by AI.
Chi Sheng Pharma & Biotech Co., Ltd. is currently trading at $29.95. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Chi Sheng Pharma & Biotech Co., Ltd. on Alpha Lenz.
View Chi Sheng Pharma & Biotech Co., Ltd.'s valuation metrics on Alpha Lenz.
“Chi Sheng Pharma & Biotech Co., Ltd.'s ROE is 12.4%. Explore profitability and growth together.”
Ask for details →Chi Sheng Pharma & Biotech Co., Ltd. is a leading pharmaceutical and biotechnology company focused on the manufacturing and distribution of medical medicines, equipment, and consumable healthcare products. Established in 1962 and headquartered in Hsinchu, Taiwan, the company has a diversified portfolio that includes injectable treatments—such as hemodialysis solutions, amino acid and vitamin injections—as well as oral medicines such as antibiotics, cough syrups, and gastrointestinal treatments. In addition to internally and externally applied pharmaceuticals, it offers products like contact lens solutions, saline, and iodine, along with healthcare foods and select medical devices. Chi Sheng Pharma & Biotech Co., Ltd. serves both the domestic Taiwanese market and exports to China and Southeast Asia. Operating within the major pharmaceuticals segment of the health technology sector, the company plays a vital role in supporting clinical care and public health infrastructure through its comprehensive product offerings and long-standing presence in the market.
“Chi Sheng Pharma & Biotech Co., Ltd.'s ROE is 12.4%. Explore profitability and growth together.”
Ask for details →Chi Sheng Pharma & Biotech Co., Ltd. (ticker: 4111) is a company listed on TWSE in the Healthcare sector (Medical Instruments & Supplies).
The current price is 29.95 with a P/E ratio of -x and P/B of -x.
ROE is 12.37% and operating margin is 14.48%. Annual revenue is $1.4B.